`
`Drug
`
`Detrol
`
`Detrol LA
`
`Ditropan XL
`
`Enablex
`
`Oxytrol
`
`Sanctura
`
`Sanctura/XR
`
`Vesicare
`
`Generic oxybutynin
`
`Other
`Total
`
`Metric
`
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Market share
`Prescriptions
`Sales
`Sales
`Sales
`
`2000
`
`[A]
`
`48.0%
`4,287.0
`
`
`324.0$
`n/a
`n/a
`n/a
`24.0%
`2,148.0
`
`
`179.0$
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`26.0%
`2,341.0
`
`
`41.0$
`
`10.0$
`
`554.0$
`
`2001
`
`[B]
`
`31.0%
`4,255.0
`
`
`310.0$
`17.0%
`2,370.0
`
`
`178.0$
`23.0%
`3,215.0
`
`
`240.0$
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`17.0%
`2,400.0
`
`
`36.0$
`
`25.0$
`
`789.0$
`
`2002
`
`[C]
`
`15.0%
`2,269.0
`
`
`185.0$
`34.0%
`5,096.0
`
`
`395.0$
`26.0%
`3,890.0
`
`
`305.0$
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`17.0%
`2,542.0
`
`
`33.0$
`
`19.0$
`
`937.0$
`
`2003
`
`[D]
`
`8.0%
`1,199.0
`
`
`102.0$
`40.0%
`6,382.0
`
`
`545.0$
`28.0%
`4,512.0
`
`
`379.0$
`n/a
`n/a
`n/a
`2.0%
`331.0
`
`
`23.0$
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`14.0%
`2,161.0
`
`
`28.0$
`
`18.0$
`
`1,095.0$
`
`2004
`
`[E]
`
`5.0%
`734.0
`
`
`90.0$
`40.0%
`5,873.0
`
`
`690.0$
`21.0%
`3,150.0
`
`
`400.0$
`n/a
`n/a
`n/a
`4.0%
`533.0
`
`
`39.0$
`1.0%
`
`76.0
`8.0$
`
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`17.0%
`2,500.0
`
`
`30.0$
`
`28.0$
`
`1,285.0$
`
`2005
`
`[F]
`
`4.0%
`780.0
`
`
`67.0$
`40.0%
`7,016.0
`
`
`608.0$
`20.0%
`3,562.0
`
`
`375.0$
`2.0%
`385.0
`
`
`35.0$
`3.0%
`492.0
`
`
`42.0$
`2.0%
`354.0
`
`
`30.0$
`n/a
`n/a
`n/a
`3.0%
`459.0
`
`
`45.0$
`15.0%
`2,654.0
`
`
`30.0$
`
`30.0$
`
`1,262.0$
`
`2006
`
`[G]
`
`4.0%
`597.0
`
`
`72.0$
`42.0%
`6,915.0
`
`
`793.0$
`16.0%
`2,662.0
`
`
`322.0$
`7.0%
`1,104.0
`
`
`118.0$
`3.0%
`441.0
`
`
`43.0$
`n/a
`n/a
`n/a
`2.0%
`389.0
`
`
`37.0$
`8.0%
`1,297.0
`
`
`144.0$
`17.0%
`2,835.0
`
`
`54.0$
`2.0$
`
`
`1,585.0$
`
`2007
`
`[H]
`
`3.0%
`509.0
`
`
`62.0$
`39.0%
`6,776.0
`
`
`800.0$
`2.0%
`362.0
`
`
`52.0$
`9.0%
`1,539.0
`
`
`150.0$
`2.0%
`395.0
`
`
`35.0$
`n/a
`n/a
`n/a
`2.0%
`429.0
`
`
`50.0$
`12.0%
`2,065.0
`
`
`245.0$
`30.0%
`5,238.0
`
`
`100.0$
`
`-$
`
`1,494.0$
`
`Notes and sources
`Prescriptions are in thousands Sales are in millions of $U S
`[A] Cowen and Company, "Therapeutic Categories Outlook," 10/2001, at 301
`[B] Cowen and Company, "Therapeutic Categories Outlook," 10/2002, at 366
`[C] Cowen and Company, "Therapeutic Categories Outlook," 10/2003, at 434
`[D] Cowen and Company, "Therapeutic Categories Outlook," 3/2004, at 522
`[E] Cowen and Company, "Therapeutic Categories Outlook," 10/2005, at 664
`[F] Cowen and Company, "Therapeutic Categories Outlook," 10/2006, at 804
`[G] Cowen and Company, "Therapeutic Categories Outlook," 10/2007, at 1020
`[H] Cowen and Company, "Therapeutic Categories Outlook," 9/2008, at 1155
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1039 - Page 1